|
Balance Sheet Cash Flow Statement 777 Old Saw Mill River Rd. Tarrytown, NY 10591 NY Tel. 914-789-2800 Fax 914-789-2817 |
Type: Public
On the web:
http://www.progenics.com
Employees:
244
Employee growth: (0.4%)
Progenics Pharmaceuticals is taking a proactive approach to fighting serious diseases such as HIV and cancer. The biotech company won its first FDA approval in 2008 with Relistor (methylnatrexone), which blocks the side effects of opioids without lessening their pain-killing power. The drug, which Progenics developed in collaboration with Wyeth Pharmaceuticals (now part of Pfizer), was approved as a treatment for opioid-induced constipation in terminally ill patients. Also in the firm's pipeline are a therapeutic vaccine for prostate cancer, as well as monoclonal antibodies for treating HIV and Hepatitis C.
Key numbers for fiscal year ending December, 2008:
Sales: $67.7M
One year growth: (10.5%)
Net income: ($44.7)M
Officers:
Chairman: Kurt W. Briner
CEO, Chief Science Officer, and Director: Paul J. Maddon
President and Director: Mark R. Baker
Competitors:
Adolor
GlaxoSmithKline
Pfizer
